HAE patient self-sampling for biomarker establishment
Abstract Background Hereditary Angioedema (HAE) is a genetic disorder that leads to frequent angioedema attacks in various parts of the body. In most cases it is caused by pathogenic variants in the SERPING1 gene, coding for C1-Inhibitor (C1-INH). The pathogenic variants in the gene result in reduce...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-021-02021-x |
id |
doaj-42ac95988cc34c619d90eabd06f998a1 |
---|---|
record_format |
Article |
spelling |
doaj-42ac95988cc34c619d90eabd06f998a12021-10-03T11:37:32ZengBMCOrphanet Journal of Rare Diseases1750-11722021-09-011611910.1186/s13023-021-02021-xHAE patient self-sampling for biomarker establishmentToni M. Förster0Markus Magerl1Marcus Maurer2Selen Zülbahar3Susanne Zielke4Neil Inhaber5Donatello Crocetta6Arndt Rolfs7Volha Skrahina8CENTOGENE GmbHDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin BerlinDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin BerlinCENTOGENE GmbHCENTOGENE GmbHTakeda Pharmaceutical Company LimitedTakeda Pharmaceuticals International AGCENTOGENE GmbHCENTOGENE GmbHAbstract Background Hereditary Angioedema (HAE) is a genetic disorder that leads to frequent angioedema attacks in various parts of the body. In most cases it is caused by pathogenic variants in the SERPING1 gene, coding for C1-Inhibitor (C1-INH). The pathogenic variants in the gene result in reduced C1-INH levels and/or activity, which causes aberrant bradykinin production and enhanced vascular permeability. The standard-of-care diagnostic test is performed biochemically via measuring C1-INH level and activity as well as the C4 level. This, however, does not allow for the diagnosis of HAE types with normal C1-INH. There is an urgent need to identify and characterize HAE biomarkers for facilitating diagnostics and personalizing the treatment. The Hereditary Angioedema Kininogen Assay (HAEKA) study aims to measure the dynamics of cleaved High Molecular Weight Kininogen (HKa) and other metabolite levels during the angioedema and non-angioedema state of the disease. The metabolites will be analyzed and verified by liquid chromatography ion mobility high resolution mass spectrometry (LC/IM-QToF MS) of dried blood spot (DBS) cards upon the study completion. The study design is truly innovative: 100 enrolled participants provide blood samples via DBS: (1) every 3 months within 2 years during regular study site visits and (2) by at-home self-sampling during HAE attacks via finger pricking. We are presenting a project design that permits clinical study activities during pandemic contact restrictions and opens the door for other clinical studies during COVID-19. Results As of October 2020, there are 41 patients from 5 sites in Germany enrolled. 90 blood samples were collected during the regular visits, and 19 of the participants also performed self-sampling during the HAE attacks from which a total of 286 attack blood samples were collected. Participating patients rate the study procedures as easy to implement in their daily lives. The concept of home self-sampling is effective, reproducible, and convenient especially in times of contact restrictions due to the COVID-19 pandemic. Conclusions It is the hope that the HAEKA study will complete in 2023, reveal biomarker(s) for monitoring HAE disease activity, and may help to avoid HAE attacks via applying medication prior to the symptom onset.https://doi.org/10.1186/s13023-021-02021-xHereditary angioedemaObservational clinical studyBiomarkerCleaved high molecular weight KininogenSelf-sampling |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Toni M. Förster Markus Magerl Marcus Maurer Selen Zülbahar Susanne Zielke Neil Inhaber Donatello Crocetta Arndt Rolfs Volha Skrahina |
spellingShingle |
Toni M. Förster Markus Magerl Marcus Maurer Selen Zülbahar Susanne Zielke Neil Inhaber Donatello Crocetta Arndt Rolfs Volha Skrahina HAE patient self-sampling for biomarker establishment Orphanet Journal of Rare Diseases Hereditary angioedema Observational clinical study Biomarker Cleaved high molecular weight Kininogen Self-sampling |
author_facet |
Toni M. Förster Markus Magerl Marcus Maurer Selen Zülbahar Susanne Zielke Neil Inhaber Donatello Crocetta Arndt Rolfs Volha Skrahina |
author_sort |
Toni M. Förster |
title |
HAE patient self-sampling for biomarker establishment |
title_short |
HAE patient self-sampling for biomarker establishment |
title_full |
HAE patient self-sampling for biomarker establishment |
title_fullStr |
HAE patient self-sampling for biomarker establishment |
title_full_unstemmed |
HAE patient self-sampling for biomarker establishment |
title_sort |
hae patient self-sampling for biomarker establishment |
publisher |
BMC |
series |
Orphanet Journal of Rare Diseases |
issn |
1750-1172 |
publishDate |
2021-09-01 |
description |
Abstract Background Hereditary Angioedema (HAE) is a genetic disorder that leads to frequent angioedema attacks in various parts of the body. In most cases it is caused by pathogenic variants in the SERPING1 gene, coding for C1-Inhibitor (C1-INH). The pathogenic variants in the gene result in reduced C1-INH levels and/or activity, which causes aberrant bradykinin production and enhanced vascular permeability. The standard-of-care diagnostic test is performed biochemically via measuring C1-INH level and activity as well as the C4 level. This, however, does not allow for the diagnosis of HAE types with normal C1-INH. There is an urgent need to identify and characterize HAE biomarkers for facilitating diagnostics and personalizing the treatment. The Hereditary Angioedema Kininogen Assay (HAEKA) study aims to measure the dynamics of cleaved High Molecular Weight Kininogen (HKa) and other metabolite levels during the angioedema and non-angioedema state of the disease. The metabolites will be analyzed and verified by liquid chromatography ion mobility high resolution mass spectrometry (LC/IM-QToF MS) of dried blood spot (DBS) cards upon the study completion. The study design is truly innovative: 100 enrolled participants provide blood samples via DBS: (1) every 3 months within 2 years during regular study site visits and (2) by at-home self-sampling during HAE attacks via finger pricking. We are presenting a project design that permits clinical study activities during pandemic contact restrictions and opens the door for other clinical studies during COVID-19. Results As of October 2020, there are 41 patients from 5 sites in Germany enrolled. 90 blood samples were collected during the regular visits, and 19 of the participants also performed self-sampling during the HAE attacks from which a total of 286 attack blood samples were collected. Participating patients rate the study procedures as easy to implement in their daily lives. The concept of home self-sampling is effective, reproducible, and convenient especially in times of contact restrictions due to the COVID-19 pandemic. Conclusions It is the hope that the HAEKA study will complete in 2023, reveal biomarker(s) for monitoring HAE disease activity, and may help to avoid HAE attacks via applying medication prior to the symptom onset. |
topic |
Hereditary angioedema Observational clinical study Biomarker Cleaved high molecular weight Kininogen Self-sampling |
url |
https://doi.org/10.1186/s13023-021-02021-x |
work_keys_str_mv |
AT tonimforster haepatientselfsamplingforbiomarkerestablishment AT markusmagerl haepatientselfsamplingforbiomarkerestablishment AT marcusmaurer haepatientselfsamplingforbiomarkerestablishment AT selenzulbahar haepatientselfsamplingforbiomarkerestablishment AT susannezielke haepatientselfsamplingforbiomarkerestablishment AT neilinhaber haepatientselfsamplingforbiomarkerestablishment AT donatellocrocetta haepatientselfsamplingforbiomarkerestablishment AT arndtrolfs haepatientselfsamplingforbiomarkerestablishment AT volhaskrahina haepatientselfsamplingforbiomarkerestablishment |
_version_ |
1716845340921954304 |